用于治疗MAFLD/MASH的他汀类药物：在等待最终答案之际的又一块基石。 - Suppr

Statins for MAFLD/MASH: another brick in the wall while waiting for final answers.

作者信息

Bosch Jaime

机构信息

Department of Visceral Surgery and Medicine (Hepatology), Inselspital Universitätsspital Bern, Bern, Switzerland

出版信息

Gut. 2025 Mar 6;74(4):518-520. doi: 10.1136/gutjnl-2024-333426.

DOI:10.1136/gutjnl-2024-333426

PMID:39299766

Abstract

摘要

相似文献

Statins for MAFLD/MASH: another brick in the wall while waiting for final answers.

Gut. 2025 Mar 6;74(4):518-520. doi: 10.1136/gutjnl-2024-333426.

Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study.

Int J Gen Med. 2024 Dec 27;17:6495-6511. doi: 10.2147/IJGM.S481724. eCollection 2024.

Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis.

J Hepatol. 2024 Aug;81(2):207-217. doi: 10.1016/j.jhep.2024.03.014. Epub 2024 Mar 18.

Pathophysiological mechanisms underlying MAFLD.

Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1875-1887. doi: 10.1016/j.dsx.2020.09.026. Epub 2020 Sep 24.

Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.

J Hepatol. 2024 Mar;80(3):467-481. doi: 10.1016/j.jhep.2023.11.001. Epub 2023 Nov 14.

Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet.

JHEP Rep. 2024 Sep 21;7(2):101222. doi: 10.1016/j.jhepr.2024.101222. eCollection 2025 Feb.

Anthropometric Indices and Metabolic Dysfunction-Associated Fatty Liver Disease in Males and Females Living With Severe Obesity.

Can J Gastroenterol Hepatol. 2025 Feb 16;2025:5545227. doi: 10.1155/cjgh/5545227. eCollection 2025.

Reversed role of CD36 deficiency in high-fat diet or methionine/choline-deficient diet-induced hepatic steatosis and steatohepatitis.

Front Pharmacol. 2025 Mar 5;16:1522177. doi: 10.3389/fphar.2025.1522177. eCollection 2025.

An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review.

Hosp Pract (1995). 2024 Oct 7:1-7. doi: 10.1080/21548331.2024.2412513.

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.

Curr Diab Rep. 2025 Feb 18;25(1):23. doi: 10.1007/s11892-025-01579-1.

引用本文的文献

Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study.

Int J Mol Sci. 2025 Jun 6;26(12):5427. doi: 10.3390/ijms26125427.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Statins for MAFLD/MASH: another brick in the wall while waiting for final answers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Statins for MAFLD/MASH: another brick in the wall while waiting for final answers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献